Related by context. All words. (Click for frequent words.) 72 PCa 67 prostate cancer CaP 65 advanced adenoma 64 advanced adenomas 64 metastatic prostate cancer 64 urothelial carcinoma 64 distant metastases 64 micrometastases 64 lobular carcinoma 64 tumor recurrence 64 biochemical recurrence 64 breast carcinoma 64 HNSCC 64 prostate cancers 63 prostate cancer PCa 63 colorectal carcinoma 63 distant metastasis 63 hepatocellular carcinoma 63 locoregional recurrence 63 HGPIN 63 adjuvant radiotherapy 63 cystectomy 63 adenomatous polyps 63 neoplasia 63 pancreatic adenocarcinoma 63 castration resistant prostate cancer 63 metastatic disease 63 gastric cancer 63 CIN2 + 63 advanced neoplasia 63 prostate carcinoma 63 epithelial ovarian cancer 63 basal cell carcinoma BCC 62 prostate adenocarcinoma 62 invasive carcinoma 62 lymph node metastases 62 colorectal cancer 62 SLNB 62 epithelial tumors 62 pCR 62 prostatic adenocarcinoma 62 atypical hyperplasia 62 gastric adenocarcinoma 62 cervical intraepithelial neoplasia 62 neoplasias 61 lymph node metastasis 61 colorectal cancer CRC 61 radical prostatectomy RP 61 EBRT 61 adenoma 61 serous ovarian cancer 61 metastatic renal cell carcinoma 61 ASCUS 61 prostate cancer CRPC 61 prostate cancer 61 breast carcinomas 61 colorectal cancers 61 univariate analysis 61 locoregional 61 localized prostate cancer 61 adjuvant therapy 61 lymphadenectomy 61 pT3 61 colorectal adenomas 60 micrometastasis 60 MGUS 60 colorectal adenoma 60 cervical carcinoma 60 pT2 60 neoadjuvant chemotherapy 60 bladder cancers 60 grade cervical intraepithelial 60 extracapsular extension 60 antigen PSA 60 malignancy 60 adenocarcinomas 60 urothelial bladder cancer 60 GSTP1 60 carcinoma 60 pelvic lymphadenectomy 60 atypia 60 androgen deprivation 60 adjuvant radiation 60 renal tumors 60 nonmetastatic 60 rs# [002] 60 HER2 expression 60 metastases 60 invasive breast cancer 60 bladder carcinoma 60 malignancies 60 nonmelanoma skin cancers 60 rs# [003] 60 germline mutations 60 T1c 60 HER2 overexpression 59 bone metastasis 59 NSCLC 59 neoplastic 59 confidence interval #.#-#.# 59 HER2 amplification 59 ovarian cancers 59 axillary lymph nodes 59 androgen deficiency 59 nodal metastases 59 varicocele 59 renal cell carcinomas 59 BRCA1 mutations 59 seminoma 59 liver metastases 59 GnRH agonists 59 adenomatous 59 FLT3 59 neoadjuvant 59 operable breast cancer 59 clinically localized prostate 59 endometrial cancers 59 estrogen receptor ER 59 hormone receptor negative 59 histologic subtype 59 BRCA2 mutation carriers 59 flutamide 59 adenocarcinoma 59 neoadjuvant therapy 59 chlamydial infection 59 prostate specific 59 K ras mutations 59 promoter methylation 59 SNP rs# [002] 59 metastatic RCC 59 MetS 59 KRAS mutation 59 metastatic malignant melanoma 59 ABCB1 59 definite stent thrombosis 59 ductal cancer 59 cervical lesions 59 lymphovascular invasion 59 Clusterin 59 neoplasm 58 prostate biopsy 58 serum PSA 58 SUVmax 58 esophageal carcinoma 58 HER2 positive cancers 58 gastric cancers 58 seminal vesicle invasion 58 gastric carcinoma 58 metachronous 58 CC genotype 58 preoperative chemotherapy 58 preoperative PSA 58 ovarian carcinoma 58 PCA3 58 neoplasms 58 NMIBC 58 peritoneal carcinomatosis 58 lymph node involvement 58 malignant pleural mesothelioma 58 malignant lesions 58 hepatocellular carcinomas 58 pancreatic cancers 58 mucinous 58 IL#B 58 5-FU/LV 58 BRCA mutations 58 biopsy Gleason 58 cutaneous melanoma 58 recurrent VTE 58 prognostic significance 58 hormone receptor positive 58 hepatocellular carcinoma HCC 58 invasive carcinomas 58 grade gliomas 58 precursor lesions 58 invasive ductal 58 carotid stenosis 58 fibroadenomas 58 immunohistochemical staining 58 prognostic factor 58 external beam radiotherapy 58 Adjuvant chemotherapy 58 prognostic biomarker 58 histologically confirmed 58 prognostic indicator 58 colorectal neoplasms 58 Immunohistochemical staining 58 adenomas 58 lobular cancer 58 testicular germ cell 58 thromboembolic disease 58 tPSA 58 osteosarcomas 58 HER2 negative 58 ADPKD 58 penetrance 58 CIN3 + 58 trabectedin 58 nonsmall cell lung cancer 58 HCV infection 58 mRCC 58 endometrial hyperplasia 58 intravesical therapy 58 GRASPA ® 58 recurrent NSCLC 58 metastatic cancer 58 breast tumors 58 squamous cell carcinoma SCC 58 contralateral breast cancer 58 lymphoproliferative disorders 58 node metastases 58 Kaplan Meier analysis 58 malignant neoplasms 58 thyroid nodules 58 pulmonary metastases 58 biliary tract cancer 58 comorbidity 58 radical nephrectomy 58 nonmelanoma skin cancer 58 medullary thyroid cancer 58 urine cytology 57 mammographic density 57 CIN3 57 HBsAg 57 TT genotype 57 adjuvant chemotherapy 57 BCG refractory 57 prognostic indicators 57 PSADT 57 transurethral resection 57 antitumor effect 57 Radical prostatectomy 57 thyroid carcinoma 57 liver metastasis 57 tumor subtypes 57 androgen independent 57 skeletal metastases 57 nonfatal MI 57 oropharyngeal cancer 57 brain metastases 57 biochemical relapse 57 rs# [004] 57 intraepithelial neoplasia 57 carcinoid tumors 57 BRAF V#E mutation 57 nonalcoholic steatohepatitis NASH 57 mesotheliomas 57 leukemia AML 57 HBeAg negative 57 clinico pathological 57 thyroglobulin 57 multivariable analysis 57 radical cystectomy 57 multivariate Cox 57 disease progression 57 histologically proven 57 colorectal liver metastases 57 BRCA1 mutation carriers 57 D dimer 57 GIST tumors 57 prostate tumor 57 adjuvant therapies 57 microsatellite instability 57 cholangiocarcinoma 57 immunohistochemical analysis 57 histological subtype 57 serum prostate 57 IGFBP 57 choroidal neovascularization 57 BRAF mutation 57 esophageal squamous cell carcinoma 57 chemoradiation 57 lymph node dissection 57 HNPCC 57 T1a 57 situ LCIS 57 prostate specific antigen 57 TACE 57 PITX2 57 endometrial carcinoma 57 NMP# 57 IGF 1R 57 thiopurine 57 decitabine 57 rs# [001] 57 lymphocytosis 57 autoantibody 57 ccRCC 57 elevated CRP 57 ALCL 57 F FDG PET 57 severe neutropenia 57 #.#ng/ml 57 hip BMD 57 chemoradiotherapy 57 colorectal neoplasia 57 HER2 positive 57 vertebral fracture 57 specific antigen PSA 57 genotypic resistance 57 breast cancer subtypes 57 breast cancers 57 BRCA2 mutations 57 EUS FNA 57 liver transplant recipients 57 carcinoids 57 Recurrence Score 57 TNF α 57 virologic failure 57 NNRTI resistance 57 T2DM 57 PTPN# 57 HER2/neu 57 mycophenolate mofetil 57 thromboembolic events 56 breast cancer recurrence 56 HLA B# 56 MALT lymphoma 56 microalbuminuria 56 PSA nadir 56 colorectal polyps 56 B7 H3 56 HPV# 56 stage IIIB 56 radical prostatectomy 56 postoperative radiotherapy 56 TRUS 56 BRCA mutation carriers 56 orchiectomy 56 endometrial cancer 56 mCRC patients 56 intravenous bisphosphonates 56 CR nPR 56 LUTS 56 Immunohistochemistry 56 FDG PET imaging 56 gene amplification 56 metastatic colorectal 56 papillary thyroid carcinoma 56 dutasteride 56 TIMP 56 relapsed ovarian cancer 56 DFMO 56 anti JCV antibodies 56 TMPRSS2 ERG 56 GISTs 56 adenoma recurrence 56 gefitinib Iressa 56 neoplasia PIN 56 metastatic lung cancer 56 histologic 56 squamous 56 intact parathyroid hormone 56 KRAS mutations 56 soft tissue sarcomas 56 tumor histology 56 endosonography 56 COX2 56 Interferon alfa 56 urothelial cancer 56 fibrosis 56 TIMP 1 56 APOL1 56 prostate cancer AIPC 56 pheochromocytoma 56 immunohistochemical 56 dysglycemia 56 liver fibrosis 56 HER-2/neu 56 familial pancreatic cancer 56 axillary dissection 56 hTERT 56 nodal metastasis 56 seminomas 56 sarcomatoid 56 recurrent ovarian 56 non squamous NSCLC 56 carcinomas 56 acute leukemias 56 NPM1 56 androgen suppression 56 axillary node dissection 56 metastatic neuroendocrine tumors 56 CD3 monoclonal antibody 56 interleukin IL -# 56 #F FDG PET 56 contralateral breast 56 endocrine therapies 56 activating mutations 56 rheumatoid factor 56 ovarian cancer 56 micafungin 56 prostate cancer mCRPC 56 hepatoma 56 obstructive coronary artery 56 chlamydial 56 venous thromboembolism 56 clodronate 56 PROSTVAC VF 56 SCCHN 56 LHRH agonists 56 colorectal tumors 56 MGd 56 chemoembolization 56 metastatic prostate 56 thromboembolism 56 neoplastic lesions 56 cTnT 56 postmenopausal breast cancer 56 mutated K ras 56 Papillary 56 CVD mortality 56 prognostic variables 56 TMPRSS2 ERG fusion 56 poorer prognosis 56 lung metastases 56 univariate analyzes 56 androgen ablation 56 Subgroup analyzes 56 PIK3CA 56 vinorelbine 56 β blockers 56 papillary carcinoma 56 elevated LDH 56 Androgen deprivation therapy 56 EGFR mutation 56 colorectal polyp 56 diabetes mellitus DM 56 atherosclerotic disease 56 breast endometrial 56 APOE e4 56 erlotinib Tarceva 56 testicular cancers 56 T SPOT.TB 56 melanoma 56 oesophageal adenocarcinoma 56 mRNA expression 56 melanomas 55 metastatic bladder 55 gastrointestinal cancers 55 H pylori 55 hypercholesterolemia 55 metastatic 55 XELOX 55 hydroxyvitamin D levels 55 estrogen receptor negative 55 diffuse gastric 55 adrenalectomy 55 radiotherapy RT 55 LHRH receptor positive 55 metaplasia 55 FOLFOX4 55 Squamous 55 ductal breast cancer 55 differentiated thyroid 55 renal cell carcinoma 55 LRP5 55 hormone deprivation 55 axillary lymph node 55 candidemia 55 highest tertile 55 IV NSCLC 55 HPV-#/# 55 latent tuberculosis infection 55 lymphomas 55 underwent radical prostatectomy 55 metastatic malignant 55 PCNSL 55 Helicobacter pylori infection 55 clinicopathological 55 epithelial ovarian 55 heterozygotes 55 prostatectomy 55 pelvic malignancies 55 basal cell carcinomas 55 prostate TURP 55 estrogen receptor positive 55 TAXUS Express Stent 55 CLL cells 55 Doxil ® 55 EGFR mutations 55 GABHS 55 perioperative morbidity 55 EGFR TKIs 55 CYP#D# 55 nomograms 55 c MYC 55 pathologic 55 HER2 positive breast cancer 55 cytoreductive nephrectomy 55 chronic HBV infection 55 idiopathic myelofibrosis 55 malignant prostate 55 cytologic 55 pretargeting 55 malignant lymphoma 55 VTE 55 IV bisphosphonates 55 renal carcinoma 55 EpCAM 55 castrate resistant prostate cancer 55 Multivariate analysis 55 imatinib therapy 55 lupus nephritis 55 intima media thickness 55 periodontitis 55 TRUS biopsy 55 KRAS mutations occur 55 gallstone disease 55 multivariate analysis 55 antibody titer 55 axillary node 55 sarcosine 55 PI3K inhibitors 55 adenoviral 55 guaiac 55 HER2 receptor 55 premenopausal breast cancer 55 nephrectomy 55 depsipeptide 55 cyclin E 55 SERMs 55 subclinical hypothyroidism 55 subclinical 55 tumorigenicity 55 breast cancer metastasis 55 AML MDS 55 superficial bladder cancer 55 Aspergillus infections 55 tamoxifen therapy 55 bladder tumors 55 bladder cancer 55 P = .# 55 diagnostic biomarker 55 IPAH 55 goserelin 55 predictive biomarker 55 BRCA2 55 coronary artery calcium 55 LHRH agonist 55 situ CIS 55 hamartomas 55 SPINK1 55 coinfected patients 55 HSCT 55 HCV infected 55 NGAL 55 clinically detectable 55 malignant nodules 55 serum testosterone 55 bone metastases 55 IDH1 mutation 55 follicular lymphoma FL 55 macroalbuminuria 55 LV dysfunction 55 % Confidence Interval 55 Acute Coronary Syndromes ACS 55 PSA velocity 55 nasopharyngeal carcinoma 55 rebleeding 55 cabazitaxel 55 CIN2 55 DMARD 55 HCV replicon 55 papillary renal cell carcinoma 55 thyroid carcinomas 55 hypogonadal 55 hepatic metastases 55 invasive coronary angiography 55 uveal melanoma 55 cutaneous squamous cell carcinoma 55 Irinotecan 55 antiangiogenic therapy 55 intestinal metaplasia 55 atrophic gastritis 55 cranial irradiation 55 C. trachomatis 55 multivariate analyzes 55 sentinel lymph node biopsy 55 CLL SLL 55 invasive lobular 55 bilateral oophorectomy 55 NRTI resistance 55 clinicopathological features 55 ErbB2 positive 55 % CI #.#-#.# [007] 55 hepatorenal syndrome 55 sDNA 55 subclinical atherosclerosis 55 PCA3 gene 55 vismodegib 55 BRCA2 mutation 55 noncarriers 55 beta blocker therapy 55 EGFR 55 NPM1 mutation 55 hyperintense lesions 55 somatic mutations 55 polyp recurrence 55 neoadjuvant treatment 55 fluoropyrimidine 55 MSH2 55 recurrent ovarian cancer 55 transitional cell carcinoma 55 LTBI 55 abdominal adiposity 55 tuberous sclerosis TS 55 grade squamous intraepithelial 55 Sjögren syndrome 55 BRCA mutation 55 premalignant 55 Wwox 55 BRCA2 carriers 55 endometrioid 55 transgene expression 55 sentinel nodes 55 interferon alfa 55 Epidermal Growth Factor Receptor 55 invasive aspergillosis 55 hyperplastic polyps 55 everolimus eluting stents 54 ductal carcinomas 54 papillary RCC 54 hematologic toxicity 54 Her2/neu 54 NADiA TM 54 asymptomatic 54 nutlin 3a 54 sorafenib Nexavar 54 pegylated liposomal doxorubicin 54 elevated triglyceride levels 54 undergone radical prostatectomy 54 nephrogenic 54 bicalutamide 54 urolithiasis 54 genomic alterations 54 EGFR gene 54 IgA deficiency 54 BRAF V#E 54 Endometrial 54 haematopoietic 54 leiomyomas 54 T#I [002] 54 Erlotinib 54 VKORC1 54 trastuzumab 54 coronary artery calcification 54 EBV infection 54 mitochondrial toxicity 54 FGFR2 54 squamous histology 54 IL 1ß 54 XIENCE V PROMUS Stent 54 PSA screening 54 benign neoplasms 54 T2D 54 acute GvHD 54 specific antigen 54 osteoblast 54 miRview ® 54 metastatic castration resistant 54 peritoneal cancer 54 myeloperoxidase 54 WT1 54 Poisson regression 54 genotypic 54 oophorectomy 54 pleural mesothelioma 54 TNFa 54 antiandrogen 54 ALND 54 core needle biopsies 54 thromboembolic complications 54 chronic prostatitis 54 TURP 54 mycosis fungoides 54 defibrotide 54 bioavailable testosterone 54 homozygotes 54 microvessel density 54 colorectal adenocarcinoma 54 venous thrombosis 54 imatinib Gleevec 54 nephron sparing surgery 54 HBeAg positive patients 54 Epigenomics proprietary 54 prognostic marker 54 follicular thyroid cancer 54 breast lesions 54 hormone refractory 54 undergoing radical prostatectomy 54 mTOR inhibitors 54 rectal cancers 54 perioperatively 54 HER2 ErbB2 54 prognostic markers 54 HBV infection 54 thromboembolic 54 PROLARIS 54 carcinoembryonic antigen 54 colorectal carcinomas 54 CYP#C# [001] 54 chromosomal rearrangement 54 lung adenocarcinomas 54 benign prostatic hypertrophy 54 neuroendocrine tumors 54 FDG PET 54 malignant growths 54 KRAS wild 54 ERBB2 54 IFN alpha 54 chemoprevention trials 54 Hepatocellular Carcinoma HCC 54 HBeAg 54 total thyroidectomy 54 tumors 54 fallopian tube carcinoma 54 -#.# ± [002] 54 pheochromocytomas 54 APTIMA HPV 54 idraparinux 54 gemcitabine Gemzar 54 octreotide LAR 54 thrombophilia 54 nonmetastatic prostate cancer 54 multiple myeloma MM 54 isoenzyme 54 Epstein Barr virus EBV 54 SNP rs# [001] 54 smoldering myeloma 54 PsA 54 CDH1 54 premalignant lesions 54 serine protease 54 TPMT 54 ALK mutations 54 detecting colorectal cancer 54 colorectal tumor 54 ECOG PS 54 effector function 54 prostate tissue 54 papillary 54 ERCC1 54 Carcinoma 54 transferrin saturation 54 Malignant Melanoma 54 endometrial thickness 54 qRT PCR 54 radioiodine therapy 54 hepatocellular cancer 54 UGT#A# 54 metastatic lesions 54 kidney allograft 54 geographic atrophy 54 CMV infection 54 microdeletions 54 intestinal polyps 54 progesterone receptor negative 54 peptide antigens 54 postoperative morbidity 54 lung metastasis 54 Leydig cell 54 adjuvant tamoxifen 54 myelofibrosis polycythemia vera 54 uterine cancers 54 Degarelix 54 serum selenium 54 cisplatin resistant 54 NAFLD 54 resectable 54 prostate pancreatic 54 HER2 positive metastatic breast 54 cytoreduction 54 ertapenem 54 curative resection 54 bone scintigraphy 54 serologic 54 lung carcinomas 54 advanced hepatocellular carcinoma 54 KRAS status 54 prognostic factors 54 Cystectomy 54 femoral neck BMD 54 invasive bladder 54 genetic polymorphisms 54 interferon IFN 54 multivariable adjusted 54 conventional angiography 54 luteinizing hormone releasing 54 TGFBR1 * 6A 54 pDCs 54 precancerous cervical lesions 54 unresectable tumors 54 intratumoral 54 HbF 54 proteinuria 54 TOP2A 54 prognostic 54 esophageal adenocarcinoma 54 predictive biomarkers 54 K ras 54 eptifibatide 54 Thalomid ® 54 Hurthle cell 54 noncardiac 54 pro angiogenic 54 lymphadenopathy 54 stage IIIA 54 Hodgkin lymphoma HL 54 contrast induced nephropathy 54 MTHFR 54 colon carcinoma 54 erlotinib 54 resected pancreatic cancer 54 follicular lymphoma 54 ocular toxicity 54 dacarbazine chemotherapy 54 atypical ductal hyperplasia 54 aminotransferases 54 posaconazole 54 FDG-PET/CT 54 papillary thyroid cancer 54 extranodal 54 Logistic regression 54 Folfox 54 systemic lupus erythematosus SLE 54 carotid IMT 54 medically inoperable 54 tumor progression 54 5alpha reductase 54 oncologic outcomes 54 ductal lobular 54 endarterectomy 54 Chlamydia pneumoniae 54 mutated KRAS 54 RASSF1A 54 recurrent prostate cancer 54 nonischemic 54 Pralatrexate 54 Cardiotoxicity 54 pancreatic NET 54 ELISPOT 54 lipid abnormalities 54 PARP inhibition 54 extracranial 54 alkylating agent 54 tibolone 54 monoclonal 54 CTAP# Capsules 54 HBeAg positive 54 histopathologic 54 troponin T 54 autoantibodies 54 univariate 54 progesterone receptor PR 54 chromosomal aberrations 54 leiomyoma 54 EGFR mutant 54 prostate colon 54 gastric cardia 54 non Hodgkin lymphomas 54 pancreatic carcinoma 54 benign breast 54 subclinical hyperthyroidism 54 cTnI 54 refractory prostate cancer 54 % CI #.#-#.# [003] 54 acid phosphatase PAP 54 R0 resection 54 sporadic ALS 54 imipenem 53 immunochemical 53 mtDNA mutations 53 paraganglioma 53 H. pylori 53 surgically resectable 53 recurrent GBM 53 K#R [002] 53 MACCE 53 delta isoform 53 colorectal gastric 53 TCF#L# 53 C#Y 53 low expressors 53 elevated ALT 53 HER2 53 completely resected 53 Leukine ® 53 Prostate Specific Antigen PSA 53 recurrent metastatic 53 allogeneic SCT 53 bendamustine 53 fallopian tube cancers 53 neuroblastomas 53 Neoadjuvant 53 #F FDG 53 apolipoproteins 53 orchitis 53 BRAF mutations 53 optical colonoscopy 53 GRP# 53 cancer mCRC 53 renal dysfunction 53 logistic regression analysis 53 lobular carcinomas 53 NSCLC tumors 53 varicoceles 53 stratify patients 53 Zolinza 53 HER2 neu 53 locoregional disease 53 excisional biopsy 53 colon tumors 53 tumor necrosis 53 noncancer 53 Adenocarcinoma 53 AST ALT 53 E#F# 53 myeloproliferative diseases 53 latent celiac disease 53 perineural invasion 53 Prostate Specific Antigen 53 androgen receptor AR 53 hyperhomocysteinemia 53 clinicopathologic 53 PROVENGE 53 activin 53 lipid lowering drugs 53 hematuria 53 Lenalidomide 53 collagenous colitis 53 PHPT 53 lobular breast cancer 53 p# biomarker 53 VATS lobectomy 53 cytological 53 recurrent glioblastoma multiforme 53 receptor tyrosine kinase inhibitor 53 idiopathic PAH 53 decompensated cirrhosis 53 immunochemical fecal occult 53 conventional coronary angiography 53 postoperative chemotherapy 53 chemosensitivity 53 Metastatic 53 paclitaxel eluting stents 53 physiologic mechanisms 53 TNFalpha 53 GH deficiency 53 carboplatin paclitaxel 53 Pseudomonas aeruginosa infections 53 androgen dependent 53 variceal hemorrhage 53 microscopic hematuria 53 CP CPPS 53 myeloproliferative disorders 53 temsirolimus 53 mammographically 53 fluoroquinolone resistance 53 HIV HCV coinfected 53 clusterin 53 cilengitide 53 lung nodules 53 allogeneic stem cell 53 malignant polyps 53 salpingo oophorectomy 53 CsA 53 hormone receptor status 53 extracapsular 53 collagen degradation 53 stratifying patients 53 IFN gamma 53 tumor lysis syndrome 53 adalimumab 53 hereditary hemochromatosis 53 primary hyperparathyroidism 53 ADRB2 53 thyrotoxicosis 53 postoperative complication 53 HPV 53 lumbar spine BMD 53 SIR Spheres microspheres 53 osteopenic 53 trans retinoic acid 53 immunostaining 53 PC3 cells 53 hypermethylation 53 postmenopausal osteoporotic women 53 microbleeds 53 hepatectomy 53 tumoral 53 bevacizumab Avastin ® 53 anti angiogenic therapy 53 partial nephrectomy 53 postmenopausal hormone 53 immunohistochemistry 53 p = #.# [003] 53 POAG 53 atopic